<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142622</url>
  </required_header>
  <id_info>
    <org_study_id>AR HSG 02 2010 Ovarian Cyst</org_study_id>
    <nct_id>NCT01142622</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Ropivacaine Nebulization for Pain Control After Gynecologic Laparoscopic Surgery</brief_title>
  <official_title>Do Peritoneal Nebulization of Ropivacaine Reduce the Use of Morphine After Short Gynecologic Laparoscopic Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Gerardo Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Gerardo Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if intraperitoneal nebulization of Ropivacaine 150 mg
      may prevent the use of morphine during the first day after laparoscopic ovarian cyst surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a recent study the investigators found that nebulization of Ropivacaine 30 mg before or
      after gynaecologic laparoscopic surgery significantly reduces postoperative pain and
      postoperative morphine consumption.

      Ropivacaine was effectively administered with non-heating nebulizers (AeronebProÂ®).

      However, almost all patients still use morphine after surgery.

      The investigators hypothesize that intraperitoneal nebulization of Ropivacaine 150 mg may
      prevent the use of morphine after the laparoscopic ovarian cyst surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption (mg)</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The total dose of morphine at every evaluation after awakening will be quantified using the PACU clinical chart and/or PCA infusers memory display.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Postoperative pain will be assessed by numeric ranking scale (NRS 0 to 10 points) at rest (static NRS) and after deep inspiration or cough (dynamic NRS). Pain after surgery will be differentiated as abdominal, wall pain, port wound pain, back pain and shoulder pain. The proportion of patients with adequate pain control after surgery (dynamic NRS &lt; 3) will also be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of unassisted walking</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Unassisted walking time is defined as the time in hours between PACU discharge and when the patient is able to walk out of his room and back to bed without any assistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital morbidity</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>All complications or adverse effects associated or possibly associated with the interventions under study, surgery or anesthesia, will be quantified using the anesthesia charts, surgical charts and surgical database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>We define hospital stay as the time in hours elapsed between surgery and hospital discharge. We evaluate the hospital stay with the post-anesthetic discharge scoring system (Modified-PADSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after surgery</measure>
    <time_frame>Four weeks after surgery</time_frame>
    <description>Quality of life will be assessed using the SF-36 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Ovarian Cysts</condition>
  <arm_group>
    <arm_group_label>Ropivacaine nebulization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine instillation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine nebulization</intervention_name>
    <description>Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.</description>
    <arm_group_label>Ropivacaine nebulization</arm_group_label>
    <other_name>Ropivacaine</other_name>
    <other_name>Nebulization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine instillation</intervention_name>
    <description>Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.</description>
    <arm_group_label>Ropivacaine instillation</arm_group_label>
    <other_name>Ropivacaine</other_name>
    <other_name>Instillation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females 18-65 years old

          -  ASA Score I-III

          -  Scheduled for ovarian cyst laparoscopic surgery

          -  Free from pain in preoperative period

          -  Not using analgesic drugs before surgery

          -  Without cognitive impairment or mental retardation

          -  Written informed consent

        Exclusion Criteria:

          -  Emergency/urgency surgery

          -  Postoperative admission in an intensive care unit

          -  Cognitive impairment or mental retardation

          -  Progressive degenerative diseases of the CNS

          -  Seizures or chronic therapy with antiepileptic drugs

          -  Severe hepatic or renal impairment

          -  Pregnancy or lactation

          -  Allergy to one of the specific drugs under study

          -  Acute infection or inflammatory chronic disease

          -  Alcohol or drug addiction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo M Ingelmo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Gerardo Hospital, Monza. Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Greib N, Schlotterbeck H, Dow WA, Joshi GP, Geny B, Diemunsch PA. An evaluation of gas humidifying devices as a means of intraperitoneal local anesthetic administration for laparoscopic surgery. Anesth Analg. 2008 Aug;107(2):549-51. doi: 10.1213/ane.0b013e318176fa1c.</citation>
    <PMID>18633034</PMID>
  </reference>
  <reference>
    <citation>Alkhamesi NA, Peck DH, Lomax D, Darzi AW. Intraperitoneal aerosolization of bupivacaine reduces postoperative pain in laparoscopic surgery: a randomized prospective controlled double-blinded clinical trial. Surg Endosc. 2007 Apr;21(4):602-6. Epub 2006 Dec 16.</citation>
    <PMID>17180268</PMID>
  </reference>
  <reference>
    <citation>Schlotterbeck H, Schaeffer R, Dow WA, Diemunsch P. Cold nebulization used to prevent heat loss during laparoscopic surgery: an experimental study in pigs. Surg Endosc. 2008 Dec;22(12):2616-20. doi: 10.1007/s00464-008-9841-z. Epub 2008 Mar 18.</citation>
    <PMID>18347861</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Gerardo Hospital</investigator_affiliation>
    <investigator_full_name>Pablo Mauricio Ingelmo M.D.</investigator_full_name>
    <investigator_title>Consultant Anesthesiologyst</investigator_title>
  </responsible_party>
  <keyword>Ovarian Cysts</keyword>
  <keyword>Nebulization</keyword>
  <keyword>Ropivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

